品名： Brilliant Violet 605™ anti-mouse/human CD44 Antibody

型号： 103047 产品详情 金山科研平台现货促销

Product Details

Isotype Control

Brilliant Violet 605™ Rat IgG2b, κ Isotype Ctrl

Verified Reactivity

Mouse, Human

Reported Reactivity

Chimpanzee, Baboon, Cynomolgus, Rhesus, Squirrel Monkey, Horse, Cow, Pig, Dog, Cat

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Dexamethasone-induced myeloid leukemia M1 cells

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone IM7 has been reported to recognize an epitope common to alloantigens and all isoforms of CD44^17,18 that is located between amino acids 145 and 186²⁰. This clone has been verified forimmunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections^6,7, complement-mediated cytotoxicity¹, immunoprecipitation^1,3, in vivo inhibition of DTH^4,5, and spatial biology (IBEX)^23,24. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103046, 103065 - 103069).Cross-reactivity to ferret has been reported by a collaborator, but not verified in house.

Application References(PubMed link indicates BioLegend citation)

See More

Trowbridge IS, et al. 1982. Immunogenetics 15:299. (ICFC, IP, CMCD)

Katoh S, et al. 1994. J. Immunol. 153:3440. (ELISA)

Budd RC, et al. 1987. J. Immunol. 138:3120. (IP)

Camp RL, et al. 1993. J. Exp. Med. 178:497. (Block)

Weiss JM, et al. 1997. J. Cell Biol. 137:1137. (Block)

Frank NY, et al. 2005. Cancer Res. 65:4320. (IHC) PubMed

Cuff CA, et al. 2001. J. Clin. Invest. 108:1031. (IHC)

Lee JW, et al. 2006. Nature Immunol. 8:181.

Zhang N, et al. 2005. J. Immunol. 174:6967. PubMed

Huabiao C, et al. 2005. J. Immunol. 175:591. PubMed

Gui J, et al. 2007. Int. Immunol. 19:1201. PubMed

Wang XY, et al. 2008. Blood 111:2436. PubMed

Product Citations

See More

Fernandez HR, et al. 2018. Cell Death Differ. 25:1239. PubMed

Young JS, et al. 2018. Front Immunol. 9:1385. PubMed

Shi H et al. 2018. Immunity. 49(5):899-914 . PubMed

Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed

Lercher A, et al. 2019. Immunity. 51:1074. PubMed

Leruste A, et al. 2020. Cancer Cell. 36(6):597-612.e8.. PubMed

McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed

Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed

Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed

Kim EH, et al. 2020. Elife. 9:00. PubMed

Dubois V, et al. 2021. NPJ Vaccines. 6:06. PubMed

Glassman CR, et al. 2021. eLife. 10:00. PubMed

RRID

AB_2562451 (BioLegend Cat. No. 103047)

金山科研平台授权一级代理，咨询微信：jinshanbio